Medical Affairs Reputations: Melanoma (EU5) 2017

Wednesday, November 8, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 7, 2017 /PRNewswire/ -- Find out what the leading team gets right, and what the trailing team gets wrongThe

medical affairs team for a leading melanoma treatment is doing all the right things in the EU5 countries. Oncologists gave it the highest overall score and the highest performance and satisfaction ratings on most medical affairs services. Meanwhile,
a rival team has done just the opposite, earning the lowest scores across the board. This report reveals how your team compares, so you can learn from those successes and failures, and build better relationships with doctors.

Read the full report: https://www.reportlinker.com/p05175255

Comparing 7 major melanoma treatments from Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, and Roche, this report reveals:Find out what more doctors want from your medical affairs team including:How doctors rate your team overall, and on 12 key medical affairs services.Which medical affairs services are most important, and what you can do to improve them.How, and how often doctors want to meet with your team.That's actionable information you can use to turn your team into one that doctors rely on.Top Takeaways

  • The right stuff: The team that earns the highest overall quality score also gets the highest performance and satisfaction scores for most medical affairs services.
  • Meanwhile, at the bottom of the pack: The team that earns the lowest overall score also trails the pack in performance and satisfaction scores for most medical affairs services.
  • Doctors are hungry for information: They identified 4 ways teams can improve information provision, and highlighted at least 1 specific type of information they want more of.
  • Four teams need specific improvements: They each need to improve at least one medical affairs service. Find out which one.
  • Calls for a better attitude: Over 20% of surveyed doctors said teams needed a better medical affairs attitude, and pointed to specific improvements.
  • Dialling in the frequency: Some teams are reaching out to doctors as often as doctors would like. Others need to reach out more often or back off a bit.

Insight into Medical Affairs Teams for These Melanoma TreatmentsImlygic (talimogene laherparepvec; Amgen)Keytruda (pembrolizumab; Merck Sharp & Dohme)Mekinist (trametinib; Novartis)Opdivo (nivolumab; Bristol-Myers Squibb)Tafinlar (dabrafenib; Novartis)Yervoy (ipilimumab; Bristol-Myers Squibb)Zelboraf (vemurafenib; Roche)An Expert-designed Competitive View of Your Medical Affairs TeamDeveloped with the help of medical affairs specialists, this report gives you an in-depth comparison of 7 medical affairs teams—answering important questions like:What do doctors need?How, and how often are they using your medical affairs team? What services do they consider most important? How often should you contact them? What channels are best? Does your medical affairs team deliver?How memorable are your team's interactions with doctors? How do doctors rank your team for performance and satisfaction in 12 key areas? How does your team compare to the competition—in each area, and overall? What needs improvement?Are you delivering the services that are most important to doctors? Where do you need to improve? How can your team enhance its services? 

Based on Interviews with Practicing DoctorsWe surveyed 150 medical oncologists and dermato-oncologists from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.All respondents: 

Have been practicing for between 3 and 35 yearsSee at least 5 patients with melanoma in a typical monthDevote at least 50% of their time to direct patient careHave interacted with at least one listed product's medical affairs team in the past 6 months. We conducted the survey between June 1st and June 7th, 2017. 

Read the full report: https://www.reportlinker.com/p05175255 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com

__________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/medical-affairs-reputations-melanoma-eu5-2017-300551436.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store